<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02071459</url>
  </required_header>
  <id_info>
    <org_study_id>12 554 01</org_study_id>
    <secondary_id>12-018-0200</secondary_id>
    <nct_id>NCT02071459</nct_id>
  </id_info>
  <brief_title>Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSA</brief_title>
  <acronym>DOPS-AMS</acronym>
  <official_title>Evaluate the Long-term (3 Months) Efficacy of L-threo DOPS (DroxiDopa) on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With Multiple System Atrophy (MSA). Comparative Study Versus Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the effects of L-Threo DOPS on orthostatic hypotension symptoms and other non-motor
      symptoms in patients with Multiple System Atrophy (MSA) after 12 weeks following
      randomization to continued therapy with droxidopa or placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background :

      Multiple system atrophy (MSA) is a rare, sporadic progressive neurodegenerative disorder,
      rapidly leading to severe disability and impairment of quality of life. MSA is characterized
      by a variable combination of a poor levodopa parkinsonism and /or cerebellar ataxia and
      autonomic failure (cardiovascular and / or bladder and sexual dysfunction) (Gilman et al,
      2008). The prevalence is approximately 4-5 cases per 100 000 inhabitants.

      Orthostatic hypotension (OH) is one of the major symptoms of MSA, present in a large majority
      of patients, leading to significant disability because of impaired balance, falls and
      possibly syncope. Drugs available to treat OH in this disease are very limited.

      L-ThreoDOPS (L DOPS or DroxiDopa) is an orally administered synthetic catecholamine acid that
      is converted to the sympathetic neurotransmitter norepinephrine (NE) through a single step of
      decarboxylation by the endogenous enzyme 3,4-dihydroxyphenylalanine (DOPA) decarboxylase. It
      prevents symptoms related to OH by central and/peripheral mechanisms. This drug is currently
      developed for &quot;neurogenic OH&quot; by Chelsea Therapeutics on the basis of short duration
      placebo-controlled randomized trials. Besides an expected effect on OH, L-DOPS may also, by
      noradrenergic stimulation, improve some motor and non-motor symptoms common and disabling in
      MSA patients such as akinesia and fatigue.

      In this context, the French reference center for MSA and the 12 national centers with
      identified skills to manage this disease, propose to conduct a national multicenter
      randomized clinical trial versus placebo to evaluate the long term efficacy (3 months) of
      L-threo DOPS on the OH and other non-motor symptoms in MSA patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the efficacy of long term efficacy of L-threo DOPS</measure>
    <time_frame>12 weeks</time_frame>
    <description>Evaluate the efficacy of long term efficacy of L-threo DOPS (droxidopa) in MSA patients (probable or possible - cerebellar (C) or parkinsonian (P) type) with symptomatic NOH as measured by the relative change in mean score of Orthostatic Hypotension Symptom Assessment (OHSA) (Part I of the questionnaire on the symptoms OH (OHQ) (Kaufmann et al., 2011)) 12 weeks following randomization to therapy with droxidopa or placebo (including 8 weeks to maximum tolerated dose).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>efficacy of L-ThreoDOPS on symptomatic OH</measure>
    <time_frame>12 weeks</time_frame>
    <description>Evaluate and compare the efficacy of L-ThreoDOPS on symptomatic OH (measured by the relative change in mean score of Item 1 of the Orthostatic Hypotension Symptom Assessment (OHSA)) in MSA patients 4, 8 and 12 weeks following randomization to continued therapy with droxidopa or placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>effects of L-Threo DOPS on motor symptoms</measure>
    <time_frame>12 weeks</time_frame>
    <description>Evaluate the effects of L-Threo DOPS on motor symptoms (UMSARS I and II) in MSA patients after 12 weeks following randomization to continued therapy with droxidopa or placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>effect of L-Threo DOPS on dysautonomic symptoms</measure>
    <time_frame>12 weeks</time_frame>
    <description>Evaluate the effect of L-Threo DOPS on dysautonomic symptoms (COMPASS) in MSA patients after 4, 8 and 12 weeks following randomization to continued therapy with droxidopa or placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety of high doses of L-ThreoDOPS</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Determine the safety of high doses of L-ThreoDOPS in MSA patients based on the occurrence of treatment-emergent adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Multiple System Atrophy</condition>
  <arm_group>
    <arm_group_label>L-Threo DOPS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with Multiple System Atrophy (MSA) after 12 weeks to continued therapy with L-Threo DOPS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients with Multiple System Atrophy (MSA) after 12 weeks to continued therapy with placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-Threo DOPS</intervention_name>
    <description>initial dose titration period (4 weeks) followed by 8 weeks at the max tolerated dose</description>
    <arm_group_label>L-Threo DOPS</arm_group_label>
    <other_name>L DOPS or DroxiDopa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>initial period (4 weeks) followed by 8 weeks</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  MSA patients (possible or probable, MSA-P or C (according to revised criteria, Gilman
             et al 2008)).

          -  Aged 30 to 80 years,

          -  Able to walk at least 10 meters

          -  With symptomatic OH (score of at least 3 at one of the items of Part I of the OH scale
             (OHQ))

          -  Documented fall in systolic blood pressure of at least 20 mmHg, and/or in diastolic
             blood pressure of at least 10 mmHg, within 3 minutes after standing.

          -  Able to fill in the evaluation questionnaires with or without help

          -  With no significant problems with swallowing.

          -  Stable anti-parkinsonian, dysautonomia and depression treatments for the 4 weeks
             before the study and during the entire study

          -  Signed written informed consent for the present study.

        Exclusion Criteria:

          -  Dementia (DSM-IV, Mini-Mental State Examination (MMSE) &lt; 24/30)

          -  Concomitant use of vaso-constrictive drugs, other than midodrine. Patients taking
             vasoconstrictor agents such as ephedrine, dihydroergotamine, must stop taking these
             drugs at least 2 days or 7 half-lives prior to their baseline visit (Visit 1); the
             association with midodrine may be kept at a stable dose not exceeding 3 tablets (7.5
             mg) / day if the patient has no CV history. This will be discussed case by case with
             the coordinating center and the safety committee of this study.

          -  Taking anti-hypertensive medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne PAVY-LE-TRAON, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ANNE PAVY-LE-TRAON, PHD</last_name>
    <phone>33(0)561772271</phone>
    <email>pavy-letraon.a@chu-toulouse.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre hospitalier d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valérie Chauviré, PHD</last_name>
      <email>vachauvire@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>valerie chauvire, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>françois Tison, PHD</last_name>
      <phone>05 57 65 64 20</phone>
      <email>francois.tison@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>François Tison, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Ulla, PHD</last_name>
      <phone>04 73 75 15 94</phone>
      <email>mulla@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>thibault Moreau, PHD</last_name>
      <phone>03 80 29 37 53</phone>
      <email>thibault.moreau@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Thibault moreau, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luc Defebvre, PHD</last_name>
      <phone>03.20.44.67.52</phone>
      <email>luc.defebvre@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Luc Defebvre, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric Torny, PHD</last_name>
      <phone>05 55 05 65 61</phone>
      <email>frederic.torny@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Frédéric Torny, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandre Eusebio, PHD</last_name>
      <phone>04 91 38 43 33</phone>
      <email>Alexandre.Eusebio@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Alexandre Eusebio, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital G. &amp; R. Laennec</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>pascal. derkinderen, PHD</last_name>
      <email>pascal.derkinderen@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>pascal. derkinderen, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié-Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Christophe Corvol, PHD</last_name>
      <phone>01 42 16 19 50</phone>
      <email>jean-christophe.corvol@psl.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>jean-christophe. corvol, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Luc Houeto, PHD</last_name>
      <phone>05 49 44 44 46</phone>
      <email>j.l.houeto@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Luc Houeto, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Sophie Drapier, PHD</last_name>
      <phone>02 99 28 98 42</phone>
      <email>sophie.drapier@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>sophie. drapier, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Maltête, PHD</last_name>
      <email>david.maltete@chu-rouen.fr</email>
    </contact>
    <investigator>
      <last_name>david. maltete, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>chu de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Tranchant, PHD</last_name>
      <phone>03 88 11 53 66</phone>
      <email>christine.tranchant@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>: christine. tranchant, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2014</study_first_submitted>
  <study_first_submitted_qc>February 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2014</study_first_posted>
  <last_update_submitted>March 5, 2017</last_update_submitted>
  <last_update_submitted_qc>March 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>L-threo DOPS (DroxiDopa)</keyword>
  <keyword>Orthostatic Hypotension</keyword>
  <keyword>Multiple system atrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Hypotension</mesh_term>
    <mesh_term>Hypotension, Orthostatic</mesh_term>
    <mesh_term>Multiple System Atrophy</mesh_term>
    <mesh_term>Shy-Drager Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Droxidopa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

